

QUALITY POLICY

Good Clinical Practices are binding reference in the field of clinical research. Their respect is under the responsibility of our customers (by delegation under our responsibility) and that of the investigator in the context of their respective obligations.

One of the obligations of our customers, formalized in good clinical practice is the establishment of a quality system as part of clinical trials. You will understand why our customers expect an investment on our part to maintain continuity in the quality management.

Pharmaspecific aims to be responsive to its customers, but also to the investigators and patients. As manager of Pharmaspecific, I pledge to orient our policy towards continuous improvement to ensure the quality of our services, to increase our efficiency, to keep our customers happy and to take into account legal and regulatory requirements.

This certification will allow us to move into new markets; we will access to more large-scale projects and develop the activities of the company.

We have the ambition to grow internationally, especially in Africa and will establish our first subsidiary of early 2017. We also want to diversify and work increasingly with specialized innovative companies on medical devices.

With this in mind, I allocate necessary resources adapted to this quality approach.

I am also committed to do everything possible for this project to be known and understood by all company personnel.

I would ask you all full adherence to this project and keep in mind that only the rules, procedures and instructions affecting our services must be specified in writing.

The implementation of an ISO 9001 quality management system will be for our customers a further guarantee of our commitment and our constantly directed investment towards their satisfaction and changing expectations.

Champs sur Marne, le 22 Décembre 2015,
General manager of Pharmaspecific
Vanessa Montanari

